Table 1.
Clinical data of vitiligo patients
| Parameter | N (%) |
|---|---|
| Stress as triggering | 117 (78) |
| Familial clustering | 95 (53.07) |
| Presence of autoimmune disorders: | 32 (16.50) |
| Hashimoto’s disease | 18 (9.28) |
| Graves’ disease | 5 (2.58) |
| Psoriasis | 4 (2.06) |
| Arthritis | 2 (1.03) |
| Other* | 3 (1.55) |
| With familial clustering and autoimmune disorder | 21 (10.83) |
| Initial macule time: | |
| Late onset (> 20 y) | 111 (57.51) |
| Early onset (< 20 y) | 82 (42.49) |
| Clinical subtype: | |
| Focal | 12 (6.19) |
| Acrofacial | 18 (9.28) |
| Generalized | 150 (77.32) |
| Universal | 14 (7.21) |
| With Koebner’s phenomenon | 46 (24.47) |
| VIDA score: | |
| –1 | 11 (5.67) |
| 0 | 66 (34.02) |
| 1 | 57 (29.38) |
| 2 | 22 (11.34) |
| 3 | 30 (15.46) |
| 4 | 8 (4.13) |
VIDA score meaning: -1, stable at least 1 year and spontaneous repigmentation; 0, stable for at least 1 year; +1, active in past 1 year; +2, active in past 6 months; +3, active in past 3 months; +4, active in past 6 weeks.
*
Included: lichen planus, ankylosing spondylitis, thrombocytopenic purpura.